by The glycomics market offers promise in understanding complex carbohydrates and glycans, which are implicated in various diseases. Glycomics research analyzes the structure, function, and interactions of glycans or carbohydrates in biological processes and systems. Key techniques used in glycomics include lectin microarrays, glycan microarrays, mass spectrometry, and capillary electrophoresis. The growing need to better understand the roles of glycans and carbohydrates in cellular functions, disease mechanisms, and potential therapeutics has driven the development of novel glycomics products, tools, and services.
Key Takeaways
Glycomics Companies  operating in the glycomics market are RayBiotech Life, Inc., Shimadzu Corporation, Asparia Glycomics, Agilent Technologies Inc., Thermo Fisher Scientific, Inc., Bruker Corporation, Merck KgaA, New England Biolabs, Takara Bio Inc, Waters Corporation, Danaher, Lectenz Bio, GlycoMimetics, Inc., Ludger Ltd., GlycoTech Corporation, Glycosyn LLC, Glykos, Inc., and Glanbia PLC.
– The global glycomics market is driven by the growing demand for glycomics applications across various therapeutic areas such as oncology, immunology, microbiology, and cardiology.
– Major players are expanding their presence globally driven by the continued growth opportunities for glycomics research across the Americas, Europe, Asia Pacific, Middle East, and Africa.
Market Key Trends
Continuous advancement in glycomics techniques such as mass spectrometry, nuclear magnetic resonance spectroscopy, and microarrays has augmented glycomic profiling and analysis capabilities. Glycomics research focusing on identifying glycan biomarkers and implications in various diseases including cancers and coronavirus infection is a key trend driving the market growth. Exploring the role of glycans in metabolism, cell proliferation and signaling using advanced glycomics tools will be an important research direction over the coming years.
The global glycomics market size is estimated to be valued at US$ 1.99 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period of 2024 to 2031.
Porter’s Analysis
Threat of new entrants: Medium as it requires significant investment in research and development to develop new products. However, emerging technologies may lower the entry barriers.
Bargaining power of buyers: High as the market is fragmented with many global and regional players. Customers can negotiate on price and quality.
Bargaining power of suppliers: Medium as there are many raw material suppliers but key inputs like enzymes have specialized manufacturers with significant know-how.
Threat of new substitutes: Low as glycomics has limited substitutes for disease diagnosis, drug designing, and biopharmaceutical applications.
Competitive rivalry: High due to many global and regional players differentiating through technology, quality, and service. Partnerships are common to leverage synergies.
Geographical Regions
North America dominates the glycomics market with the largest value share mainly due to significant research funding, presence of leading companies, and advanced healthcare infrastructure. The US accounts for the major market owing to supportive initiatives for glycobiology research from bodies like the National Institutes of Health.
Asia Pacific is poised to be the fastest growing region during the forecast period owing to increasing healthcare expenditures, growing biopharmaceutical industry, and improving research capabilities in countries like China, Japan, and India. Glycobiology research is gaining priority in these nations to address the rising disease burden.
Author Bio:
Ravina Pandya,Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
